Articles published in Journal of Diabetes & Metabolism have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Metabolism has got h-index 43, which means every article in Journal of Diabetes & Metabolism has got 43 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Metabolism.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
Total published articles |
123 | 107 | 59 | 61 | 45 | 23 |
Research, Review articles and Editorials |
44 | 54 | 37 | 40 | 21 | 22 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
5 | 1 | 2 | 5 | 3 | 0 |
Conference proceedings |
6 | 16 | 5 | 7 | 0 | 45 |
Citations received as per Google Scholar, other indexing platforms and portals |
632 | 946 | 1156 | 1199 | 1039 | 1106 |
| Journal total citations count | 10648 |
| Journal impact factor | 12.50 |
| Journal 5 years impact factor | 18.23 |
| Journal cite score | 23.62 |
| Journal h-index | 43 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal citescore |
| Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Nishant T, Hima Bindu K, Sathish Kumar D, Arun Kumar R. Pharmacogenomics-Personalized treatment of cancer, diabetes and cardiovascular diseases. J Pharmacogenomics Pharmacoproteomics. 2011;2:107. |
|
Gaitonde P, Garhyan P, Link C, Chien JY, Trame MN, Schmidt S. A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development. Clinical pharmacokinetics. 2016 Jul 1;55(7):769-88. |
|
Rusinov VL, Sapozhnikova IM, Bliznik AM, Chupakhin ON, Charushin VN, Spasov AA, Vassiliev PM, Kuznetsova VA, Rashchenko AI, Babkov DA. Synthesis and Evaluation of Novel [1, 2, 4] Triazolo [5, 1â€c][1, 2, 4]â€triazines and Pyrazolo [5, 1â€c][1, 2, 4] triazines as Potential Antidiabetic Agents. Archiv der Pharmazie. 2017 May;350(5):1600361. |
|
Sai YR, Dattatreya A, Anand SY, Suresh Babu D, Sandeep Heni RS. Biomarkers of internal origin and their significance in diabetes and diabetic complications. J Diabetes Metab. 2011;2. |
|
Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell death discovery. 2016 Jan 18;2:15072. |
|
Srivastava JK, Dubey P, Singh S, Bhat HR, Kumawat MK, Singh UP. Discovery of novel 1, 3, 5-triazine-thiazolidine-2, 4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of type 2 diabetes. RSC Advances. 2015;5(19):14095-102. |
|
Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. American Journal of Physiology-Endocrinology and Metabolism. 2016 Jul 12;311(2):E461-70. |
|
HimaBindu A, Soumya D. Incidence of Diabetes and its Control Measures in AIDS Patients. J Diabetes Metab. 2011;2(169):2. |
|
Maia LG, Alves AV, Bastos TS, Moromizato LS, Lima-Verde IB, Ribeiro MA, Júnior LG, de Albuquerque-Júnior RL. Histological analysis of the periodontal ligament and alveolar bone during dental movement in diabetic rats subjected to low-level laser therapy. Journal of Photochemistry and Photobiology B: Biology. 2014 Jun 5;135:65-74. |
|
Vanita P, Jhansi K. Metabolic syndrome in endocrine system. J diabetes Metab. 2011;2(163):2. |
|
Crosby-Nwaobi R, Chatziralli I, Sergentanis T, Dew T, Forbes A, et al. (2015) Cross talk between lipid metabolism and inflammatory markers in patients with diabetic retinopathy. Journal of diabetes research 29: 15. |
|
Chan JC, Ozaki R, Luk A, Kong AP, Ma RC, et al. (2014) Delivery of integrated diabetes care using logistics and information technology–The Joint Asia Diabetes Evaluation (JADE) program. Diabetes research and clinical practice 106: S295-S304. |
|
Wan EY, Fung CS, Choi EP, Wong CK, Chan AK, et al. (2016) Main predictors in health-related quality of life in Chinese patients with type 2 diabetes mellitus. Quality of Life Research 25: 2957-2965. |
|
Cai C, Hu J (2016) Effectiveness of a Family-based Diabetes Self-management Educational Intervention for Chinese Adults With Type 2 Diabetes in Wuhan, China. The Diabetes Educator 42: 697-711. |
|
Chan JC, Ozaki R, Luk A, Kong AP, Ma RC, et al. (2014) Delivery of integrated diabetes care using logistics and information technology–The Joint Asia Diabetes Evaluation (JADE) program. Diabetes research and clinical practice 106: S295-S304. |
|
Basanta-Alario ML, Ferri J, Civera M, Martínez-Hervás S, Ascaso JF, et al. (2016) Diferencias en las características clínico-biológicas y prevalencia de complicaciones crónicas en relación con el envejecimiento de pacientes con diabetes tipo 2. Endocrinología y Nutrición 29: 79-86. |
|
LA PD, TIPUS DM, CATALUNYA A. DIABETIS AVUI (2011)Diabetes rehabilitation |
|
Mata-Cases M, Franch-Nadal J, Real J, Mauricio D (2016) Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study. BMJ open 6: e012463. |
|
Barrotâ€de la Puente J, Mataâ€Cases M, Franchâ€Nadal J, Mundetâ€Tudurí X, Casellas A, et al. (2015) Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database. International journal of clinical practice 69: 1486-1495. |
|
Franch-Nadal J, Roura-Olmeda P, Benito-Badorrey B, Rodriguez-Poncelas A, Coll-de-Tuero G, et al. (2015) GEDAPS (Primary care Group for the study of Diabetes. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. Family practice 32: 27-34. |
|
